Please ensure Javascript is enabled for purposes of website accessibility

Kaléo receives $150 million debt financing

//April 7, 2014//

Kaléo receives $150 million debt financing

// April 7, 2014//

Listen to this article

Richmond-based kaléo announced Monday it has entered into a $150 million debt facility with Nevada-based PDL BioPharma. The funds will allow kaléo to support the commercialization of its anti-overdose-injector EVZIO, invest in the development of key pipeline products and repay existing debt.


EVZIO, approved by the Federal Drug Administration last week, is a pre-filled, single-use auto-injector that can be used by family members or caregivers to treat a person known or suspected to have an opioid overdose.


PDL BioPharma manages a portfolio of patents and royalty assets, consisting primarily of its Queen et al. antibody humanization patents and license agreements with various biotechnology and pharmaceutical companies

-
YOUR NEWS.
YOUR INBOX.
DAILY.

By subscribing you agree to our Privacy Policy.